Key stats
- Market cap
- 26.1B
- Open
- —
- Day range
- —
- 52-week range
- $19.32 – $42.50
- Volume
- 74.8K
- Avg volume
- 6.63M
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.